A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

Authors

J. Kellogg Parsons, Moores Cancer Center
Peter A. Pinto, National Cancer Institute (NCI)
Christian P. Pavlovich, Johns Hopkins Bayview Medical Center
Edward Uchio, University of California, Irvine
Hyung L. Kim, Cedars-Sinai Medical Center
Mikel N. Nguyen, University of Southern California
James L. Gulley, National Cancer Institute (NCI)
Christina Jamieson, Moores Cancer Center
Paul Hsu, University of Arizona Cancer Center
Margarita Wojtowicz, National Cancer Institute (NCI)
Howard Parnes, National Cancer Institute (NCI)
Jeffrey Schlom, National Cancer Institute (NCI)
William L. Dahut, National Cancer Institute (NCI)
Ravi A. Madan, National Cancer Institute (NCI)
Renee N. Donahue, National Cancer Institute (NCI)
H. H.Sherry Chow, University of Arizona Cancer Center

Document Type

Journal Article

Publication Date

9-1-2018

Journal

European Urology Focus

Volume

4

Issue

5

DOI

10.1016/j.euf.2018.08.016

Abstract

© 2018 European Association of Urology The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.

APA Citation

Parsons, J., Pinto, P., Pavlovich, C., Uchio, E., Kim, H., Nguyen, M., Gulley, J., Jamieson, C., Hsu, P., Wojtowicz, M., Parnes, H., Schlom, J., Dahut, W., Madan, R., Donahue, R., & Chow, H. (2018). A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. European Urology Focus, 4 (5). http://dx.doi.org/10.1016/j.euf.2018.08.016